RE:ASCO relevanceGeneman,
I recall someone with a similar nic on the old Yahoo board.
Yes, of course, actual work is being done on pela (former reoslyn) as evidenced in great detail on the company web site. Less work is being done on the story, per se. The company seems more than willing to let their clinical results do the talking.
Personally, I am not over my skiis regarding the upcoming presentation. I just wait because there is no other choice.
Perhaps I was over my skiis about 10 years ago when I first bought into this company.
But, IMHO, the present time offers a very good risk reward prospect, given the array of encouraging results as an I/O adjuvant or part of a cocktail with combo and a CI. And of course given the current share price.
So yes we are waiting for the breast results.